WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC and Phamadule Morimatsu Achieve Milestone with Successful Shipment of ADC Modular Facilities for Singapore Manufacturing Site
Shanghai, China, October 14, 2024 – In the global biopharmaceutical industry, the innovation and production of antibody-drug conjugates (ADCs) and other bioconjugates(XDCs) are increasingly recognized as critical drivers of industry growth, offering transformative...
WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth
Revenue surged by 67.6% YoY to RMB 1,665 million Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023. Net profit increased by 175.5% to RMB 488 million, with a net profit margin of...WuXi XDC: Bioconjugation Service Overview
Payload and Linker Services Overview
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?